418 related articles for article (PubMed ID: 25773479)
1. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
Rasool MF; Khalil F; Läer S
Clin Pharmacokinet; 2015 Sep; 54(9):943-62. PubMed ID: 25773479
[TBL] [Abstract][Full Text] [Related]
2. Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalil F; Läer S
Drug Metab Dispos; 2016 Jul; 44(7):1103-15. PubMed ID: 27068272
[TBL] [Abstract][Full Text] [Related]
3. Author's Reply to Zheng et al.: A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows.
Rasool MF; Khalil F; Läer S
Clin Pharmacokinet; 2016 Jan; 55(1):139-41. PubMed ID: 26649872
[No Abstract] [Full Text] [Related]
4. Comment on: "A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood".
Li GF; Gu X; Yu G; Zhao SY; Zheng QS
Clin Pharmacokinet; 2016 Jan; 55(1):133-7. PubMed ID: 26649873
[No Abstract] [Full Text] [Related]
5. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.
Rasool MF; Khalil F; Läer S
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):383-396. PubMed ID: 27313074
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.
Albers S; Meibohm B; Mir TS; Läer S
Br J Clin Pharmacol; 2008 Apr; 65(4):511-22. PubMed ID: 17995971
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug-drug interaction in healthy adults and its extrapolation to virtual chronic heart failure patients for dose optimization.
Rasool MF; Läer S
Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):717-724. PubMed ID: 33910429
[No Abstract] [Full Text] [Related]
9. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters.
Läer S; Mir TS; Behn F; Eiselt M; Scholz H; Venzke A; Meibohm B; Weil J
Am Heart J; 2002 May; 143(5):916-22. PubMed ID: 12040358
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases.
Rasool MF; Ali S; Khalid S; Khalid R; Majeed A; Imran I; Saeed H; Usman M; Ali M; Alali AS; AlAsmari AF; Ali N; Asiri AM; Alasmari F; Alqahtani F
Sci Rep; 2021 Apr; 11(1):8589. PubMed ID: 33883647
[TBL] [Abstract][Full Text] [Related]
11. [CLINICAL EFFICACY OF THE RECEPTOR BETA AND ALPHA BLOCKERS - CARVEDILOL AND ORNITHINE-ASPARTATE IN PATIENTS WITH CHD AND CHF COMBINED WITH ALCOHOLIC LIVER DISEASE].
Evdokimova AG; Tomova AV; Tereshchenko OI; Zhukolenko LV; Evdokimov VV
Eksp Klin Gastroenterol; 2016; (6):42-7. PubMed ID: 30280552
[TBL] [Abstract][Full Text] [Related]
12. Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
Heitmann M; Davidsen U; Stokholm KH; Rasmussen K; Burchardt H; Petersen EB
Scand J Clin Lab Invest; 2002; 62(2):97-104. PubMed ID: 12004934
[TBL] [Abstract][Full Text] [Related]
13. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure.
Tenero D; Boike S; Boyle D; Ilson B; Fesniak HF; Brozena S; Jorkasky D
J Clin Pharmacol; 2000 Aug; 40(8):844-53. PubMed ID: 10934668
[TBL] [Abstract][Full Text] [Related]
14. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure.
Krämer BK; Ress KM; Erley CM; Risler T
Eur J Clin Pharmacol; 1992; 43(1):85-8. PubMed ID: 1505616
[TBL] [Abstract][Full Text] [Related]
16. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.
Björkman S
Br J Clin Pharmacol; 2005 Jun; 59(6):691-704. PubMed ID: 15948934
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
Horiuchi I; Nozawa T; Fujii N; Inoue H; Honda M; Shimizu T; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529
[TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.
Khalil F; Läer S
AAPS J; 2014 Mar; 16(2):226-39. PubMed ID: 24399240
[TBL] [Abstract][Full Text] [Related]
19. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
20. Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products.
Ibarra M; Valiante C; Sopeña P; Schiavo A; Lorier M; Vázquez M; Fagiolino P
Eur J Pharm Sci; 2018 Jun; 118():176-182. PubMed ID: 29605455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
